Articles

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA, USA
Sarah Cannon Research Institute, Nashville, TN, USA
Sarah Cannon Research Institute, Nashville, TN, USA;Florida Cancer Specialists, Sarasota, FL, USA
Curis Inc., Lexington, MA, USA
Curis Inc., Lexington, MA, USA
Curis Inc., Lexington, MA, USA
Curis Inc., Lexington, MA, USA
Curis Inc., Lexington, MA, USA
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Vol. 102 No. 11 (2017): November, 2017 https://doi.org/10.3324/haematol.2017.172882